2、本次会议于 2024 年 3 月 14 日以通讯方式召开。 3、会议应参与表决董事 8 人，实际参与表决 8 人。 4、本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和公 司章程的规定。 二、董事局会议审议情况 证券代码：000009 证券简称：中国宝安 公告编号：2024-001 中国宝安集团股份有限公司第十四届董事局 第四十七次会议决议公告 本公司及董事局全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 一、董事局会议召开情况 1、公司第十四届董事局第四十七次会议的会议通知于 2024 年 3 月 8 日以电 话、书面或邮件等方式发出。 特此公告 中国宝安集团股份有限公司董事局 二〇二四年三月十五日 1 审议通过了《关于下属子公司拟签署合资协议暨对外投资的议案》，同意贝 特瑞（香港）新材料有限公司与 STELLAR INVESTMENT PTE. LTD.公司签署《年 产 8 万吨新能源锂电池负极材料一体化项目合资协议之补充协议（二）》，共同 增资印尼贝特瑞新能源材料有限公司，并建设年产 8 万吨新能源锂电池负极材料 一体化项目。具体内容详见同日披露的《 ...

证券代码：000009 证券简称：中国宝安 公告编号：2023-039 中国宝安集团股份有限公司 关于下属子公司拟签署《投资协议》暨对外投资 的公告 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或者重大遗漏。 一、对外投资概述 中国宝安集团股份有限公司（以下简称"公司"）下属子公司贝特瑞（江苏） 新材料科技有限公司及其全资子公司 BNUO INTERNATIONAL HOLDING PTE. LTD.（以下简称"BNUO 公司"）为实施锂电池正极材料战略布局，拟与摩洛哥王 国签署《投资协议》，计划通过 BNUO 公司在摩洛哥设立项目公司投资建设年产 5 万吨锂电池正极材料项目，项目预计总投资额不超过人民币 35.35 亿元。 公司于 2023 年 12 月 27 日召开的第十四届董事局第四十六次会议审议通过 了《关于下属子公司拟签署<投资协议>暨对外投资的议案》，详见同日披露的《第 十四届董事局第四十六次会议决议公告》。本次交易不构成关联交易，也不构成 《上市公司重大资产重组管理办法》规定的重大资产重组。根据《深圳证券交易 所股票上市规则》及《公司章程》等相关规定，本次 ...

3、会议应参与表决董事 8 人，实际参与表决 8 人。 4、本次会议的召开符合有关法律、行政法规、部门规章、规范性文件和公 司章程的规定。 二、董事局会议审议情况 证券代码：000009 证券简称：中国宝安 公告编号：2023-038 中国宝安集团股份有限公司第十四届董事局 第四十六次会议决议公告 本公司及董事局全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 一、董事局会议召开情况 1、公司第十四届董事局第四十六次会议的会议通知于 2023 年 12 月 22 日以 电话、书面或邮件等方式发出。 2、本次会议于 2023 年 12 月 27 日以通讯方式召开。 1、审议通过了《关于下属子公司拟签署<投资协议>暨对外投资的议案》， 同 意 贝特瑞（江苏）新材料科技有限公司及其全资子公司 BNUO INTERNATIONAL HOLDING PTE. LTD.（以下简称"BNUO 公司"）与摩洛哥 王国签署《投资协议》，通过 BNUO 公司在摩洛哥设立项目公司投资建设年产 5 万吨锂电池正极材料项目。具体内容详见同日披露的《关于下属子公司拟签署< 投资协议>暨对外投资的公告》 ...

中国宝安集团股份有限公司 独立董事专门会议制度 第一条 为充分发挥独立董事在公司治理中的作用，根据《上市公司独立董 事管理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司 规范运作》等有关规定，特制订本制度。 第二条 独立董事专门会议是指全部由独立董事参加的会议。独立董事是指 不在公司担任除董事外的其他职务，并与公司及其主要股东、实际控制人不存在 直接或间接利害关系，或者其他可能影响其进行独立客观判断关系的董事。 第三条 公司不定期召开独立董事专门会议，原则上于会议召开前 3 日通知 全体独立董事并提供相关资料和信息。如遇特殊情况，经全体独立董事一致同意， 通知时限可不受本条款限制。 第四条 独立董事专门会议应由三分之二以上的独立董事出席方可举行；独 立董事应当亲自出席独立董事专门会议。因故不能亲自出席会议的，独立董事应 当事先审阅会议材料，形成明确的意见，并书面委托其他独立董事代为出席。 第五条 独立董事专门会议可以通过现场、通讯（包括视频、电话、传真、 电子邮件等）方式召开，或现场与通讯相结合的方式召开。 第六条 独立董事专门会议的表决，实行一人一票，表决方式包括举手表决、 书面表决等 ...

Financial Performance - The company's operating revenue for Q3 2023 was ¥8,225,433,605.49, representing a decrease of 8.28% compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2023 was ¥186,852,024.02, an increase of 22.65% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥238,222,209.75, up 58.85% from the previous year[4]. - Basic earnings per share for Q3 2023 was ¥0.0725, reflecting a growth of 22.88% year-on-year[4]. - The net profit for Q3 2023 was CNY 1,489,456,704.40, a decrease from CNY 1,558,784,901.19 in Q3 2022, representing a decline of approximately 4.4%[17]. - The total profit for Q3 2023 was CNY 1,909,710,596.36, compared to CNY 1,858,685,920.06 in Q3 2022, indicating a growth of about 2.8%[17]. - The operating profit for Q3 2023 was CNY 1,912,579,458.96, slightly higher than CNY 1,875,209,265.23 in Q3 2022, showing an increase of approximately 2.4%[17]. - The total comprehensive income for Q3 2023 was CNY 1,496,651,119.16, down from CNY 1,585,282,325.66 in Q3 2022, representing a decrease of approximately 5.6%[18]. Cash Flow - The net cash flow from operating activities for the year-to-date period reached ¥3,924,570,676.43, a significant increase of 1,820.89% compared to the same period last year[4]. - The net cash flow from operating activities for Q3 2023 was ¥3,924,570,676.43, a significant improvement from a net outflow of ¥228,054,074.04 in Q3 2022[20]. - Total cash inflow from investment activities was ¥2,790,656,816.54, compared to ¥2,702,799,717.04 in the same period last year[20]. - The net cash flow from investment activities showed a loss of ¥1,949,288,105.46, an improvement from a loss of ¥3,649,689,361.48 in Q3 2022[20]. - Cash inflow from financing activities totaled ¥6,086,231,876.96, down from ¥12,409,939,796.56 in Q3 2022[20]. - The net cash flow from financing activities was negative at -¥1,976,766,556.51, compared to a positive flow of ¥4,166,008,995.66 in the previous year[20]. - The total cash and cash equivalents at the end of Q3 2023 amounted to ¥7,881,683,236.20, an increase from ¥6,377,775,854.83 at the end of Q3 2022[20]. Assets and Liabilities - Total assets at the end of the reporting period were ¥52,293,310,406.08, a decrease of 4.02% from the previous year-end[4]. - The total assets decreased to ¥50,278,681,050.20 from ¥52,385,798,596.69, a reduction of 4%[15]. - The total liabilities decreased to ¥29,962,565,922.47 from ¥33,542,017,842.73, a decline of 10.5%[15]. - The company reported a total asset value of ¥52,385,798,596.69 as of January 1, 2023, reflecting an increase from ¥52,293,310,406.08 at the end of 2022[23]. - The total liabilities rose from ¥33,450,764,548.03 at the end of 2022 to ¥33,542,017,842.73 as of January 1, 2023[23]. Equity - The equity attributable to shareholders at the end of the reporting period was ¥9,133,813,548.67, an increase of 7.76% compared to the previous year-end[4]. - The company’s total equity increased to ¥20,316,115,127.73 from ¥18,843,780,753.96, reflecting a growth of 7.8%[15]. - The company’s total equity attributable to shareholders increased slightly from ¥9,133,813,548.67 at the end of 2022 to ¥9,135,864,452.50 as of January 1, 2023[23]. Investment and Financing - The company increased its long-term borrowings by 82.45%, reaching ¥8,995,465,306.31 due to new long-term loans[7]. - The company reported a significant increase in long-term borrowings, which rose to ¥8,995,465,306.31 from ¥4,930,271,374.05, an increase of 82%[15]. - Interest income decreased by 69.90% to ¥8,301,218.20 compared to ¥27,574,921.59 in the same period last year due to the contraction of microloan business[8]. - Investment income fell by 59.00% to ¥175,858,733.30 from ¥428,963,478.75, primarily due to high investment returns from joint ventures in the previous year[8]. Impairment Losses - The company’s subsidiaries reported a significant reduction in credit impairment losses by 76.63% to -¥27,349,016.51, compared to -¥117,032,081.55 in the previous year[8]. - The company’s subsidiaries reported an increase in asset impairment losses by 228.15% to -¥69,447,034.73, attributed to increased inventory write-downs due to market conditions[8]. Other Agreements and Projects - The company completed the transfer of 59.469 million shares of Shenzhen Dafu Pharmaceutical Co., Ltd. at ¥4.38 per share to Hangzhou Yunbai Pharmaceutical Technology Co., Ltd.[11]. - The company signed a supplementary agreement for the urban renewal project in Longgang District, Shenzhen, focusing on "urban renewal + benefit coordination"[11]. - A joint venture agreement was amended to adjust the construction site for a new energy lithium battery anode material project in Indonesia[11].

中国宝安集团股份有限公司 2023 年半年度报告全文 2023 年半年度报告 2023 年 08 月 1 中国宝安集团股份有限公司 2023 年半年度报告全文 第一节 重要提示、目录和释义 公司董事局、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人陈政立、主管会计工作负责人贺德华及会计机构负责人(会计 主管人员)吴海涛声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事局会议。 公司已在本报告中详细描述公司存在的风险因素，敬请查阅第三节管理层 讨论与分析中关于公司面临的风险和应对措施部分内容。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 中国宝安集团股份有限公司 2023 年半年度报告全文 目录 | --- | --- | --- | |-------|-----------------------------------------------|-------| | | | | | | 第一节 重要提示、目录和释义 | | | | 第二节 公司简 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥8,228,499,170.23, representing a 44.78% increase compared to ¥5,683,423,572.87 in the same period last year[3] - The net profit attributable to shareholders for Q1 2023 was ¥239,346,190.45, up 44.94% from ¥165,134,224.14 in the previous year[3] - The basic earnings per share for Q1 2023 was ¥0.0928, reflecting a 45.00% increase from ¥0.0640 in the same period last year[3] - The net profit for Q1 2023 was CNY 466,266,526.51, an increase from CNY 450,961,686.24 in the same period last year, representing a growth of approximately 3%[15] - The total revenue from operating activities reached CNY 8,474,847,685.66, compared to CNY 4,512,263,714.73 in Q1 2022, indicating a significant increase of about 88%[17] Cash Flow and Liquidity - The net cash flow from operating activities reached ¥1,727,503,958.72, a significant increase of 464.39% compared to -¥474,078,022.77 in Q1 2022[3] - The cash and cash equivalents net increase for Q1 2023 was ¥1,036,730,692.66, a 267.47% rise from -¥619,058,999.24 in the same period last year[7] - The company's cash and cash equivalents at the end of Q1 2023 amount to ¥10,070,952,149.69, a decrease from ¥10,531,615,227.89 at the beginning of the year[11] - The cash flow from operating activities generated a net amount of CNY 1,727,503,958.72, a turnaround from a negative cash flow of CNY -474,078,022.77 in Q1 2022[17] - The company experienced a net cash outflow from investing activities of CNY -727,360,643.47, an improvement from CNY -1,619,628,525.05 in the previous year[18] Assets and Liabilities - Total assets at the end of Q1 2023 were ¥51,389,870,782.13, a decrease of 1.73% from ¥52,293,310,406.08 at the end of the previous year[3] - Non-current liabilities totaled ¥10,687,425,012.07, an increase from ¥9,258,839,983.57 year-over-year[13] - The company's cash and cash equivalents decreased to ¥6,657,890,346.84 from ¥8,315,457,905.76, a decline of 20%[13] - Total current assets are reported at ¥33,509,545,238.03, down from ¥34,986,065,478.91 at the start of the year[11] - Accounts receivable stand at ¥6,067,883,624.75, compared to ¥6,372,524,173.95 at the beginning of the year, indicating a decrease[11] Shareholder Information - The total number of common shareholders at the end of the reporting period is 226,236, with the top 10 shareholders holding a combined 40.17% of shares[8] - The largest shareholder, Shenzhen Chengxing Investment Co., Ltd., holds 16.55% of shares, totaling 426,868,042 shares[8] - The total number of shares held by the largest three shareholders is 448,710,475, representing 17.40% of the total shares[9] Investment and Expenses - The company reported a significant increase in investment income of 287.32%, amounting to ¥276,739,569.40, compared to ¥71,450,432.04 in the previous year[6] - The company experienced a 56.63% increase in operating costs, totaling ¥6,703,674,818.06, compared to ¥4,279,926,891.25 in Q1 2022[6] - Research and development expenses rose to ¥312,568,379.95, compared to ¥254,263,898.68 in the previous year, marking an increase of 23%[14] Other Information - The company has not disclosed any new product developments or market expansion strategies in the current report[10] - There is no indication of any mergers or acquisitions in the current financial report[10] - The total assets impairment loss for Q1 2023 was CNY -43,011,591.77, contrasting with a gain of CNY 3,545,680.11 in Q1 2022[15] - The company reported a total comprehensive income of CNY 443,624,965.03 for Q1 2023, slightly up from CNY 442,967,681.48 in the same quarter last year[16]

Dividend and Shareholder Information - The company plans to distribute a cash dividend of 0.35 CNY per 10 shares to all shareholders, based on a total of 2,579,213,965 shares[2]. - The company distributed a cash dividend of ¥0.35 per 10 shares, totaling ¥90,272,488.77, which represents 100% of the total profit distribution[114][115]. - The company reported a total distributable profit of ¥395,102,959.66 at the end of the reporting period[115]. Financial Performance - The company's operating revenue for 2022 was ¥31,998,720,906.66, representing an increase of 82.29% compared to ¥17,553,419,112.71 in 2021[12]. - The net profit attributable to shareholders for 2022 was ¥1,156,580,360.59, an increase of 11.68% from ¥1,035,599,088.75 in 2021[12]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥680,810,615.67, up 75.72% from ¥387,441,388.95 in 2021[12]. - The net cash flow from operating activities for 2022 was ¥290,476,146.61, a significant improvement from a negative cash flow of ¥279,272,690.50 in 2021, marking a 204.01% increase[12]. - The total assets at the end of 2022 were ¥52,293,310,406.08, a 41.05% increase from ¥37,073,195,202.73 at the end of 2021[13]. - The net assets attributable to shareholders at the end of 2022 were ¥9,133,813,548.67, reflecting a 14.17% increase from ¥8,000,289,198.35 at the end of 2021[13]. - The company achieved a weighted average return on equity of 13.49% in 2022, slightly down from 13.90% in 2021[12]. Business Operations and Strategy - The company reported significant changes in its business scope, including investments in new materials and high-tech industries since 2014[10]. - The company has undergone several changes in its business operations, including real estate development and modern biomedicine projects[10]. - The company is focused on high-tech industries, including new energy materials and electric vehicles, aligning with national strategic initiatives for industry upgrades[20]. - The company plans to continue developing new technologies and expanding its market presence in strategic emerging industries, enhancing its operational capabilities[20]. - The company aims to develop functional health products leveraging existing technology, brand, and channels, while continuously innovating and upgrading its business model[22]. Research and Development - The company reported a significant increase in R&D expenses, totaling ¥1,508,490,891.16, which is an 86.90% increase compared to ¥807,125,218.97 in 2021[49]. - The number of R&D personnel increased to 1,557 in 2022, up 24.86% from 1,247 in 2021[54]. - R&D investment amounted to ¥1,521,111,792.01 in 2022, representing an 87.36% increase from ¥811,884,198.00 in 2021[56]. - The proportion of R&D investment to operating revenue rose to 4.75% in 2022 from 4.63% in 2021, an increase of 0.12%[56]. Environmental Compliance - The company strictly adheres to environmental protection laws and industry standards in its production and operational activities[125]. - The company and its subsidiaries are classified as key pollutant discharging units by environmental protection authorities[125]. - The company has obtained pollution discharge permits for its subsidiaries, ensuring compliance with environmental regulations[126]. - The total COD emissions for 2022 were 0.038 tons, with ammonia nitrogen at 0.0001 tons and phosphate at 0.0005 tons[127]. - The company has implemented measures to ensure that emissions meet the required standards after treatment[128]. Governance and Management - The company maintains a governance structure compliant with legal regulations, ensuring independent operation without major shareholder interference[86]. - The company has established independent financial and operational systems, ensuring no asset misappropriation by major shareholders[86]. - The company has a diverse board with members holding various professional qualifications, including registered accountants and legal professionals[93]. - The company has maintained stability in its leadership with no reported changes in directors or senior management during the reporting period[90]. Market and Industry Challenges - The real estate market faced unprecedented challenges in 2022, but policies are being implemented to stabilize and support the sector[23]. - The biopharmaceutical sector is under pressure from regulatory changes and the need for new business development to ensure sustainable growth[81]. - The company faces risks related to industry policies, technological obsolescence, and supply chain dynamics, with measures in place to mitigate these risks[80]. Legal and Compliance Issues - The total amount involved in the lawsuit against Shenzhen Yuntong Logistics Co., Ltd. and others is approximately 670.72 million RMB, with a claim for full compensation of this amount[145]. - The court has taken preservation measures on assets valued at approximately 670.72 million RMB belonging to the defendants, but the lawsuit has not yet been concluded[145]. - There were no significant penalties or rectifications reported during the reporting period[147]. Shareholder Structure - The company has no controlling shareholder or actual controller since 2009, with the top two shareholders holding 8.34% and 6.95% respectively[10]. - The largest shareholder holds 16.04% of the company, with the second and third largest shareholders holding 15.04% and 5.92% respectively, indicating a diversified ownership structure[86]. - The total number of ordinary shareholders at the end of the reporting period was 226,073[165]. Financial Instruments and Debt Management - The company has issued a total of three bonds, with a total amount raised of CNY 2.05 billion, including CNY 1 billion for the 2017 bond, CNY 300 million for the 2021 bond, and CNY 750 million for the 2022 bond[174][176]. - The company has maintained its debt repayment mechanisms and plans without any changes during the reporting period, ensuring investor rights are protected[178]. - The company has not reported any overdue bonds during the reporting period, indicating a stable financial position[178]. Community Engagement and Social Responsibility - The company donated over 90 million yuan in total for social responsibility initiatives, including 15.6 million yuan worth of medicines to impoverished areas in 2022[138]. - The company organized 68 health events, benefiting over 110,000 community residents with free health check-ups[138]. - The company has committed to ongoing support for rural revitalization efforts, including cash donations and product purchases[138].